Prosecution Insights
Last updated: November 04, 2026
Application No. 18/418,817

METHOD AND MULTISENSORY DEVICE FOR NON-INVASIVE BLOOD GLUCOSE LEVEL MONITORING

Final Rejection §101§112
Filed
Jan 22, 2024
Priority
May 23, 2016 — RU 2016119799 +2 more
Examiner
KREMER, MATTHEW
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Lcm Biosensor Technologies Inc.
OA Round
2 (Final)
44%
Grant Probability
Moderate
3-4
OA Rounds
1y 4m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
201 granted / 461 resolved
-26.4% vs TC avg
Strong +52% interview lift
Without
With
+52.2%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
55 currently pending
Career history
525
Total Applications
across all art units

Statute-Specific Performance

§101
8.1%
-31.9% vs TC avg
§103
32.4%
-7.6% vs TC avg
§102
8.9%
-31.1% vs TC avg
§112
43.5%
+3.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 461 resolved cases

Office Action

§101 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Claims 1-3, 6-9, 12-16, and 23-35 are withdrawn from consideration. In the reply filed on 5/11/2026, the Applicant’s election without traverse was of species A1, A2, and A3. Elected species A1 is drawn to the detection of an amount of water in the controlled volume of tissue using an electrometric sensor. Also, species A3 is drawn to a measurement of the amount of intracellular water via electro-impedance that measures electrical impedance of tissue between electrodes. Both elected species A1 and A3 are not compatible with the new recitation of claim 1 in which a sensor measures thermophysical characteristics of the stratum corneum of the skin. In particular, the feature of “another sensor configured to detect an amount of water in the controlled volume of tissue and to output an electrical signal representative of an osmotic pressure in the controlled volume of tissue…wherein the processor is configured to determine an enthalpy of the controlled volume of tissue from the measured temperature, the measured adjustable applicator pressure, and the measured climatic parameters, to calculate a thermal effect of metabolism of the controlled volume of tissue from the determined enthalpy, and to determine the blood glucose level of the subject from the calculated thermal effect” of claim 1 is characteristic of non-elected species C1, rather than characteristic of elected species A1. Additionally, the recitation of claim 1 is also not characteristic of elected species A3. Thus, claim 1 and its dependent claims are withdrawn from consideration as being drawn to a non-elected species. Claims 11, 17, and 21 read on the elected species and are hereby examined. Information Disclosure Statement The information disclosure statement filed 1/22/2024 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document; each non-patent literature publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. There seems to be no complete copy in this application or in the parent application 16/303371 of the following foreign documents: RU 2245673, RU 141656, RU 2004124332, and RU 2013122844. These references have not been considered. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. No claim limitations are interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. Claim Objections Claims 11, 17, and 21 are objected to because of the following informalities: in claim 11, line 16: “the” should be inserted before “tissue”; in claim 11, line 17: “the” should be inserted before “tissue”; in claim 11, line 19: “the” should be inserted before “tissue”; in claim 11, line 27: “the” should be inserted before “tissue”; in claim 11, line 29: “the” should be inserted before “tissue”; in claim 17, line 3: “the” should be inserted before “tissue”; and in claim 21, line 3:“the” should be inserted before “tissue”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 11, 17, and 21 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 11 recites “tissue” in line 20, but it is not clear if this recitation is the same as, related to, or different from “tissue” of claim 11, line 10. The relationship between these two recitations should be made clear. Claim 11 recites “one or more climatic sensors configured to measure climatic parameters comprising at least an ambient air temperature and a relative humidity of ambient air” in lines 21-22, but it is not clear how one sensor measures both an ambient air temperature and a relative humidity of ambient air. These parameters are usually thought of as being measured by two different kinds of sensors. This deviation between the claim language and what one of ordinary skill in the art would consider to be the required number of sensors creates confusion that renders claim 11 indefinite. Claim 11 recites “blood glucose level” in line 30, but it is not clear if this recitation is the same as, related to, a subset of, or different from “blood glucose levels” of claim 11, line 1. If they are the same, consistent terminology should be used. If they are different, their relationship should be made clear and they should be clearly distinguished from each other (e.g., when multiple elements have similar or the same labels, distinct identifiers such as “first” and “second” should be used to clearly differentiate the elements) Claims 17 and 21 are rejected by virtue of their dependence from claim 11. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Section 33(a) of the America Invents Act reads as follows: Notwithstanding any other provision of law, no patent may issue on a claim directed to or encompassing a human organism. Claims 11, 17, and 21 are rejected under 35 U.S.C. 101 and section 33(a) of the America Invents Act as being directed to or encompassing a human organism. See also Animals - Patentability, 1077 Off. Gaz. Pat. Office 24 (April 21, 1987) (indicating that human organisms are excluded from the scope of patentable subject matter under 35 U.S.C. 101). Claim 11 recites “the applicator being thermally insulating and waterproof so as to form, together with a controlled volume of tissue of the subject beneath the applicator, a closed system that is thermally and diffusionally isolated from an environment surrounding the applicator” in lines 9-12, which inextricably links the device to a human such that the human forms part of the claimed device. It is improper to include a human as part of a claimed device. Claims 17 and 21 are rejected by virtue of their dependence from claim 11. Allowable Subject Matter Claims 11, 17, and 21 would be allowable if rewritten to overcome the claim objections, the rejections under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, and the rejections under 35 U.S.C. 101 and section 33(a) of the America Invents Act set forth in this Office action. The following is a statement of reasons for the indication of allowable subject matter. RU 2396897 (Musin)(previously cited)1 teaches a device comprising a multi-sensor system configured to: convert into an electrical signal osmotic pressure in a controlled volume of tissue of the subject (obtaining osmotic pressure of intercellular substance using a sensor; pages 12, 21, 23-28, and 32 of Musin; claims 11-12, 16, 50-51, 57, and 62 of Musin), measure physiological parameters characterizing osmotic pressure in the controlled volume of tissue (measuring glucose concentration; pages 12 and 32 and claims 165-166, and 171-173 of Musin), and measure climatic parameters (measuring external pressure, temperature, and humidity; pages 12 and 32 and claims 153, 159, 165, and 171-173 of Musin). The device of Musin also includes a waterproof applicator of a device configured to create linear displacement and adjustable applicator pressure on the surface of the stratum corneum of the epidermis (the waterproof applicator that applies a metered pressure to the surface of the stratum corneum of the epidermis; page 17 and claims 16, 163, 167 of Musin), a temperature sensor (claim 125, 127, 160, 167, 171-173, 183, and 191 of Musin), and another sensor configured to detect an amount of water in the controlled volume of tissue (pages 1, 11-13, and 17-21 and claims 124, 126, 127, 130-141, 151, 158, 165, and 171-172 of Musin). Musin also teaches a processor (claim 152 of Musin). U.S. Patent Application Publication No. 2018/0263539 (Javey)(previously cited) teaches a wearable glucose sensor (paragraph 0012, 0046, and 0064 and claim 42 of Javey; see also claims 7, 25, 30, and 40 of the provisional application 62/233,955). Javey teaches that such wearable sensors include one or more amplifiers; one or more filters; an A/D converter; a digital processor; a wireless interface configured to transmit information corresponding to the conditioned sensor signals to a remote computing device for sharing or uploading the data to could servers online; and a battery configured to power at least portions of the wearable system (paragraphs 0008, 0056, and 0061 and claim 41 of Javey; see also pages 5-6 and claims 23, 28, and 38 of the provisional application 62/233,955). The amplifiers, the filters, the wireless interface, and the battery are mounted on a substrate (claim 24 of Javey; claim 16 of the provisional application 62/233,955). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to include one or more amplifiers; one or more filters; an A/D converter; a wireless interface; and a battery to the circuits of Musin since (1) the one or more amplifiers improves the signal magnitude for better processing; (2) the one or more filters removes unwanted noise from the signals for better processing; (3) the A/D converter provides a mechanism for the processor of Musin to be utilized with the sensors of Musin; (4) the wireless interface permits transmission of the data to a remote computing device for sharing or storage; and (5) the battery powers the components of the circuit of Musin. U.S. Patent Application Publication No. 2017/0011210 (Cheong)(previously cited) teaches the use of a wearable arrangement for a sensing system that measures one or more of the user's blood pressure, blood flow, heart rate (HRM, HRV), temperature, respiration rate, oxygen saturation, cardiorespiratory sound detection, blood sugar, calorie consumption (paragraph 0458 of Cheong). The wearable arrangement includes a main body 10 and a strap 50 (paragraph 0307 of Cheong). The strap 50 has a seating portion 51 with an opening 51a into which the main body 10 is inserted using the fastening groove arrangement (paragraphs 0279-0281, 0310, 0317-0318, 0326, 0364, 0372, and 0374-0376 of Cheong). For the main body 10, Cheong teaches that the sensing portions are positioned on the lower surface of the housing and the operational components are attached to one or more circuit boards (paragraphs 0207, 332-0333, and 0339-0342 and FIGS. 10 and 13 of Cheong). Javey also teaches that amplifiers, filters, interfaces, and batteries are mounted on a substrate (claim 24 of Javey; claim 16 of the provisional application 62/233,955). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to formulate the one or more amplifiers, the one or more filters, the A/D converter, the wireless interface, the battery, the sensors, and the waterproof applicator within a housing which is insertable into a strap having a seating portion since it protects the components while permitting interchangeability of parts. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have the one or more amplifiers, the one or more filters, the A/D converter, the wireless interface, the battery, and the processor anchored to a circuit board, as suggested by Cheong and Javey, since it stabilizes the relative placements of the devices. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have the one or more sensors positioned on the lower surface of the housing, as suggested by Cheong, so as to have unobstructed access to the measurement site. Musin teaches a waterproof applicator of a device configured to create linear displacement and adjustable applicator pressure on the surface of the stratum corneum of the epidermis (the waterproof applicator that applies a metered pressure to the surface of the stratum corneum of the epidermis; page 17 and claims 16, 163, 167 of Musin). WO 2010/005406 (Vedat)(previously cited) teaches that making a structure heat resistant and water-impermeable makes such a device more durable (pages 12-13 of Vedat). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to make the waterproof applicator of Musin heat resistant since it makes the applicator more durable. Thus, the combination teaches or suggests a device for monitoring blood glucose levels of a subject having skin, the device comprising: a strap (the strap 50 of Cheong) with a mounting platform (the seating portion 51 of Cheong); a removable housing (the housing 10 suggested by Cheong) including a lower wall having at least one through hole (the housing 10 of Cheong includes holes in tis lower walls for the sensors; See FIG. 10 of Cheong), the removable housing being configured to snap onto the mounting platform (the groove arrangement of Cheong; paragraphs 0279-0281, 0310, 0317-0318, 0326, 0364, 0372, and 0374-0376 of Cheong), the lower wall being configured to contact and be pressed against a surface of the stratum corneum of the epidermis of the skin with a dosed pressure via the strap (paragraphs 0309, 0331, and 0346-0347 of Cheong); a multi-sensor system comprising: an applicator (the waterproof applicator that applies a metered pressure to the surface of the stratum corneum of the epidermis; page 17 and claims 16, 163, 167 of Musin; the waterproof applicator also being heat resistant as suggested by Vedat) disposed inside the removable housing, the applicator being thermally insulating and waterproof so as to form, together with a controlled volume of tissue of the subject beneath the applicator, a closed system that is thermally and diffusionally isolated from an environment surrounding the applicator, and the applicator being configured to create linear displacement and an adjustable applicator pressure on the surface of the stratum corneum of the epidermis, a temperature sensor (claim 125, 127, 160, 167, 171-173, 183, and 191 of Musin) configured to measure a temperature of the controlled volume of tissue beneath the applicator, and another sensor (the electrometric electrodes; pages 1, 11-13, and 17-21 and claims 124, 126, 127, 130-148, 151, 158, 165, and 171-172 of Musin) configured to detect an amount of water in the controlled volume of tissue and to output an electrical signal representative of an osmotic pressure in the controlled volume of tissue, the another sensor comprising electrodes configured to measure an electrical impedance of tissue between the electrodes, and one or more climatic sensors configured to measure climatic parameters comprising at least an ambient air temperature and a relative humidity of ambient air (sensors measuring external temperature and humidity; pages 3, 6-8, 12, 21, 32, and 35-36 and claims 4, 38, 42, 56, 125, 153, 159, 165, 167, 171-173, 183, and 191 of Musin); and an electronic board (the circuit board suggested by Javey and Cheong) and a power supply (the battery of Javey), the multi-sensor system being operably coupled to the electronic board, the electronic board including preamps (the one or more amplifiers of Javey), an analog-digital converter (the A/D converter of Javey), a processor (the processor of Musin), and a wireless transceiver (the interface of Javey); However, the prior art does not teach or suggest “wherein the processor is configured to determine an amount of intracellular water in the controlled volume of tissue from the measured electrical impedance, to determine an intracellular osmotic pressure in the controlled volume of tissue from the determined amount of intracellular water, and to determine the blood glucose level of the subject based at least in part on the determined intracellular osmotic pressure” along with the other features of claim 11. Claims 17 and 21 are allowable by virtue of their dependence from claim 11. Response to Arguments The Applicant's arguments filed on 9/9/2026 have been fully considered. Drawings In view of the new drawings submitted on 9/9/2026, the drawing objections are withdrawn. Information disclosure statement The Applicant asserts: PNG media_image1.png 152 900 media_image1.png Greyscale This argument is not persuasive. Though it is true that portions of RU 2245673, RU 141656, RU 2004124332, and RU 2013122844 were filed in the parent application 16/303371, no complete copies of these references were filed in this application or in the parent application 16/303371. These references have not been considered. Claim objections There are new grounds of claim objections that were necessitated by the claim amendments filed on 9/9/2026. 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph There are new grounds of claim rejections under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, that were necessitated by the claim amendments filed on 9/9/2026. 35 U.S.C. 101 and section 33(a) of the America Invents Act There are new grounds of claim rejections under 35 U.S.C. 101 and section 33(a) of the America Invents Act that were necessitated by the claim amendments filed on 9/9/2026. Prior art rejections The claim amendments filed on 9/9/2026 renders the previous claim rejections moot since the claims previously rejected under the prior art now read on a non-elected species. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MATTHEW KREMER whose telephone number is (571)270-3394. The examiner can normally be reached Monday - Friday 8 am to 6 pm; every other Friday off. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JACQUELINE CHENG can be reached at (571) 272-5596. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MATTHEW KREMER/Primary Examiner, Art Unit 3791 1 Citations to Musin will refer to the machine English translation that accompanied the Office Action mailed on 6/9/2026.
Read full office action

Prosecution Timeline

Jan 22, 2024
Application Filed
Jun 09, 2026
Non-Final Rejection mailed — §101, §112
Sep 09, 2026
Response Filed
Oct 30, 2026
Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12741126
DUAL-DENSITY FORMULATIONS DEVICES AND METHODS FOR INTRANASAL DRUG DELIVERY OR SAMPLING
1y 4m to grant Granted Sep 22, 2026
Patent 12733848
FLUID CONTROL DEVICES AND METHODS OF USING THE SAME
4y 10m to grant Granted Sep 15, 2026
Patent 12733849
FLUID CONTROL DEVICES AND METHODS OF USING THE SAME
4y 7m to grant Granted Sep 15, 2026
Patent 12721566
Display Of Monitored Patient Position Information
4y 5m to grant Granted Sep 01, 2026
Patent 12685826
SHEATHS FOR NEEDLE DELIVERY
4y 0m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
44%
Grant Probability
96%
With Interview (+52.2%)
4y 1m (~1y 4m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 461 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month